Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1864-1871

  Metz, Richard ^a   DuHadaway, James B ^b   Rust, Sonja ^b   Munn, David H ^c   Muller, Alexander J ^b,e   Mautino, Mario ^a   Prendergast, George C ^b,d,e  

^a New Link Genetics Corporation   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PROTOPORPHYRIN ZINC; PROTOPORPHYRIN ZINC IX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; DRUG INHIBITION; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOMA; TUMOR IMMUNITY;

ANIMALS; CELL LINE; HEME OXYGENASE-1; HUMANS; IMMUNE TOLERANCE; IMMUNITY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE; NEOPLASMS; PROTOPORPHYRINS;

EID: 77953450359     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0185     Document Type: Article

References (24)

1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
2. Prendergast GC, Jaffee EM, editors. Cancer immunotherapy: immune suppression and tumor growth. New York: Academic Press; 2007.
3. Katz JB, Muller AJ, Metz R, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008;222:206-21.
4. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008;27:3889-900.
5. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006;18:220-5.
6. + regulatory T cells is dependent on expression of heme oxygenase-1 in antigen-presenting cells. Am J Pathol 2008;173:154-60.
7. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009;183:2475-83.
8. Fang J, Sawa T, Akaike T, et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 2003;63:3567-74.
9. Fang J, Sawa T, Akaike T, Greish K, Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 2004;109:1-8. (Pubitemid 38165358)
10. Hirai K, Sasahira T, Ohmori H, Fujii K, Kuniyasu H. Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int J Cancer 2007;120:500-5. (Pubitemid 44969019)
11. Nowis D, Bugajski M, Winiarska M, et al. Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. BMC Cancer 2008;8:197.
12. Metz R, DuHadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor IDO inhibitory compound D-1MT. Cancer Res 2007;67:7082-7.
13. Gaspari P, Banerjee T, Malachowski WP, et al. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2006;49:684-92. (Pubitemid 43157498)
14. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 2004;61:67-77. (Pubitemid 38446980)
15. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801.
16. Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 2005;9:831-49.
17. Muller AJ, DuHadaway JB, Sutanto-Ward E, Donover PS, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunomodulatory target of the tumor suppressor gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9. (Pubitemid 40460560)
18. Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC. Immunotherapeutic suppression of IDO and tumor growth by ethyl pyruvate. Cancer Res 2010;70:1845-53.
19. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114:280-90. (Pubitemid 39071633)
20. Banerjee T, DuHadaway JB, Gaspari P, et al. Antitumor properties of chemopreventive natural product brassinin are based upon inhibition of indoleamine 2,3-dioxygenase (IDO). Oncogene 2007;27:2851-7.
21. Kumar S, Malachowski WP, DuHadaway JB, et al. Indoleamine 2,3- dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem 2008;51:1706-18. (Pubitemid 351438852)
22. Kumar S, Malachowski WP, DuHadaway JB, et al. Naphthaquinone-based compounds as potent inhibitors of immunoregulatory enzyme indoleamine 2,3-dioxygenase and cancer. J Med Chem 2007;51:1709-18.
23. Orabona C, Pallotta MT, Volpi C, et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A 2008;105:20828-33.
24. Labbe RF, Vreman HJ, Stevenson DK. Zinc protoporphyrin: a metabolite with a mission. Clin Chem 1999;45:2060-72.